Which oncotype DX Recurrence Score (RS) threshold, as established by the TAILORx trial, allows patients with ER+/HER2−, node-negative breast cancer to safely omit adjuvant chemotherapy and receive endocrine therapy alone?
- A RS ≤ 25 ✓
- B RS < 11
- C RS ≤ 18
- D RS < 31
Correct answer: A. RS ≤ 25
Explanation
The TAILORx trial definitively showed that patients aged >50 years with ER+/HER2−, node-negative breast cancer and an Oncotype DX RS of 0–25 had equivalent outcomes with endocrine therapy alone compared to chemotherapy plus endocrine therapy; chemotherapy adds benefit only for RS 26–100. An RS <11 was the older threshold from the original validation study. Options C and D reflect incorrect thresholds.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.